缺氧对培养的肺动脉内皮细胞血管紧张素Ⅱ分泌的影响

缺氧是否通过影响血管内皮细胞的分泌功能而参与缺氧性肺动脉高压的发生尚不清楚。本实验动态观察了缺氧对培养的新生小牛内皮细胞（ＰＡＥＣ）的血管紧张素Ⅱ（ＡＴⅡ）分泌的影响。结果发现：２．５％Ｏ２缺氧早期（１．５ｈ）,ＰＡＥＣ的ＡＴⅡ分泌增加（Ｐ＜０．０１ｖｓ常氧组）,缺氧后期与常氧组无明显差别;０％Ｏ２缺氧早期（１．５－６ｈ）,ＡＴⅡ分泌明显降低（Ｐ＜０．０１ｖｓ常氧组及２．５％Ｏ２组）,后期ＡＴⅡ分泌明显增高（Ｐ＜０．０１ｖｓ常氧组及２．５％Ｏ２组）;无论缺氧还是常氧条件下,ＮＯ供体ＳＩＮ１显著抑制ＡＴⅡ的分泌（Ｐ＜０．０１）,而内源性ＮＯ抑制剂硝基精氨酸则明显促进ＡＴⅡ分泌（Ｐ＜０．０１）;０％Ｏ２缺氧２４ｈ后,ＰＡＥＣ细胞内ｃＧＭＰ含量明显降低（Ｐ＜０．０５）。上述结果表明缺氧可通过抑制ＰＡＥＣ的内源性ＮＯ产生而促进ＡＴⅡ的分泌,ＰＡＥＣ自分泌的改变可能参与缺氧性肺动脉高压的发生过程。     

缺氧对肺动脉内皮细胞环氧合酶,血栓素合成酶基因表达的影响

应用分子杂交技术和放射免疫检测方法研究了缺氧对猪肺动脉内皮细胞的环氧合酶（ＣＯＸ）和血栓素合成酶（ＴＸＳ）基因表达及其条件培养基中６ｋｅｔｏＰＧＦ１α和ＴＸＢ２含量的动态变化。发现：６,１２,２４和４８ｈ缺氧组分别与常氧组比,ＣＯＸ１和ＣＯＸ２基因表达增加,并且ＣＯＸ２ｍＲＮＡ在缺氧６和１２ｈ就明显表达增加。在前述的不同缺氧时间组内皮细胞条件培养基中６ｋｅｔｏＰＧＦ１α含量也均显著高于相应常氧对照组（Ｐ＜０．０５）;但ＴＸＳ的ｍＲＮＡ水平及ＴＸＢ２含量在缺氧４８ｈ才有明显增加（Ｐ＜０．０５）。结果表明：（１）缺氧可诱导肺动脉内皮ＣＯＸ基因表达和ＰＧＩ２生成增加,在早期以ＣＯＸ２基因表达增加更为明显,提示可能在肺血管缺氧反应中起调节作用。（２）４８ｈ的缺氧可使内皮细胞ＴＸＳ基因表达及ＴＸＡ２生成增加,它可能在慢性缺氧肺血管反应中起介导作用。     

慢性常压缺氧和缺氧伴CO_2潴留大鼠红细胞变形能力与能量代谢的研究

本工作研究了慢性常压缺氧和缺氧伴ＣＯ＿２潴留肺动脉高压大鼠红细胞变形能力和红细胞内ＡＴＰ含量的变化。结果表明,慢性常压缺氧和缺氧伴ＣＯ＿２潴留大鼠不同切应力下的红细胞变形指数和红细胞内ＡＴＰ含量均明显低于其对照组,且该两组红细胞内ＡＴＰ含量与不同切应力下的红细胞变形指数呈显著正相关。提示慢性缺氧和伴ＣＯ＿２潴留大鼠红细胞内ＡＴＰ含量降低可能是导致红细胞变形能力降低的诸因素之一,后者又可导致和加重肺动脉高压的形成。     

慢性常压缺氧和缺氧伴CO2潴留大鼠红细胞变形能力与能…

本工作研究了慢性常压缺氧和缺氧件ＣＯ２潴留肺动脉高压大鼠红细胞变形能力和红细胞内ＡＴＰ含量的变化。结果表明，慢性常压缺氧和缺氧伴ＣＯ２潴留大鼠不同切应力下的红细胞变形指数和红细胞内ＡＴＰ含量均明显低于其对照组，且该两组红细胞内ＡＴＰ含量与不同切应力下的红细胞变形指数呈显著正相关。提示慢性缺氧和伴ＣＯ２潴留大鼠红细胞内ＡＴＰ含量降低可能是导致红细胞变形能力降低的诸因素之一，后者又可导致和加重肺动脉高     

缺氧时培养的肺动脉平滑肌细胞血管紧张素Ⅱ自分泌的变化及其机制

缺氧是否通过影响血管平滑肌细胞的自分泌功能而参与缺氧性肺动脉高压的发生尚不清楚。本实验动态了缺氧对培养的新生小牛肺动脉平滑肌细胞（ＰＡＳＭＣｓ）的血管紧张素Ⅱ（ＡＴⅡ）分泌的影响。结果发现：２．５％Ｏ２缺氧导致ＰＡＳＭＣｓ的ＡＴⅡ分泌降低,０％Ｏ２缺氧进一步抑制ＡＴⅡ分泌。常氧条件下,ＮＯ供体ＳＩＮ－１显著的抑制ＡＴⅡ分泌,而ＮＯ合酶凶制剂硝基精氨酸（ＬＮＡ）则能消除缺氧对ＡＴⅡ分泌的抑制作用。０     

高原低氧性肺动脉高压的多普勒超声研究

应用脉冲式或连续式多普勒超声技术,对１８例海拔３２００ｍ高原正常人及２５例高原心脏病（ＨＡＨＤ）患者测定其肺动脉压。正常组及ＨＡＨＤ无瓣膜返流组１０例应用Ｈａｈａｍ回归方程,肺动脉平均压（ＰＡＭＰ）分别为２．８４±０．４及３．７３±０．５７ｋＰａ（ｋＰａ＝７．５ｍｍＨｇ）;ＨＡＨＤ有三尖瓣返流组８例用ＴＲＰＧ法测得ＰＡＳＰ为６．１３±１．７３ｋＰａ;ＨＡＨＤ有肺动脉瓣返流组Ｔ例用ＰＲＰＧ法测得ＰＡＤＰ为４．０±０．７３ｋＰａ。表明多普勒超声技术的不同方法可用于不同病理状态下高原低氧性肺动脉高压的测定,并可揭示出现瓣膜返流改变时高原低氧性肺动脉高压的程度。     

过氧化氢和次黄嘌呤＋黄嘌呤氧化酶对家兔离体肺、脑动脉环缺氧反应的影响

在家兔离体肺内动脉、脑基底动脉环观察了过氧化氢（Ｈ２Ｏ２）及次黄嘌呤＋黄嘌呤氧化酶（ＨＸ＋ＸＯ）对动脉环缺氧反应的影响。结果发现：（１）Ｈ２Ｏ２１×１０－５ｍｏｌ／Ｌ加强ｆ去内皮肺动脉环（ＰＡ－）的缺氧收缩幅度（ＴＩＨ）,而Ｈ２Ｏ２３×１０－５ｍｏｌ／Ｌ、ＨＸ１０－４ｍｏｌ／Ｌ＋ＸＯ０．１及０．０３Ｕ／ｍｌ则可抑制内皮完整肺动脉环（ＰＡ＋）及ＰＡ－的ＴＩＨ（Ｐ＜０．０５）;（２）各剂量Ｈ２Ｏ２及ＨＸ＋ＸＯ对有、无内皮的脑基底动脉环的ＴＩＨ均无显著影响。     

慢性缺氧大鼠肺动脉内皮依赖性舒张反应与内皮结构的动态变化

本实验对慢性减压缺氧（５０００ｍ）过程中肺动脉ＡＣｈ内皮依赖性舒张反应作了动态观察,并结合分析了其与内皮超微结构和肺动脉压演变的关系。结果表明,缺氧３─２１ｄ,平均肺动脉压（ｍＰＡＰ）显著递增（Ｐ＜０．０５─０．００１）,而缺氧４０ｄ组基本与缺氧２１ｄ组持平,未再进一步升高。缺氧１ｄ组,各ＡＣｈ浓度（１０－１０、１０－９、１０－７、１０－６、１０－５ｍｏｌ／Ｌ）引起的内皮依赖性舒张反应明显受抑（Ｐ＜０．０５─０．００１）。缺氧７ｄ组,舒张反应的受抑程度与缺氧１ｄ组基本相同;但ＡＣｈ１０－５ｍｏｌ／Ｌ引发的反应则较缺氧１ｄ时更弱。缺氧２１ｄ和４０ｄ组,ＡＣｈ１０－６和１０－５ｍｏｌ／Ｌ引起的舒张反应,尽管仍显著低于对照,但却基本上高于缺氧１ｄ和７ｄ组。其余各浓度ＡＣｈ引发的反应则已趋于恢复至对照水平。电镜观察,缺氧１─１４ｄ肺动脉内皮呈逐渐加重的水肿变性;缺氧２１─４０ｄ内皮水肿消失,代之出现渐趋活跃的内皮增生。结果提示,随缺氧时间延长,因内皮从损伤逐渐加重到出现代偿适应,可能存在相应的内皮舒张因子由释放减少到有所恢复的动态变化过程,并对整体肺动脉压有一定程度的影响。     

缺氧对体外培养的肺动脉平滑肌细胞形态及增殖的影响

本实验应用形态学、免疫组化染色,＾３Ｈ－ＴｄＲ掺入、流式细胞等技术探讨缺氧（〈１％Ｏ２和２．５％Ｏ２）对肺动脉平滑肌细胞（ＰＡＳＭ）形态及增殖的影响。结果表明：缺氧２４ｈ使ＰＡＳＭ表型从收缩型向合成型转换,胞浆内ＳＭ－ａ ａｃｔｉｎ减少,线粒体和粗面内质网增多,缺氧４８ｈ以后线粒体肿胀,空泡化,内质网扩张,胞浆内出现髓鞘样结构。流式细胞分析显示缺氧ＰＡＳＭ Ｇ２／Ｍ期细胞比例明显增多（Ｐ〈０．００     

慢性缺氧大鼠肺动脉内皮依赖性舒张反应与内皮结构的动态…

本实验对慢性减压缺氧（５０００ｍ）过程中肺动脉ＡＣｈ内皮依赖性舒张反应作了动态观察,并结合分析了其与内皮超微结构和肺动脉压演变的关系。结果表明,缺氧３－２１ｄ,平均肺动脉压（ｍＰＡＰ）显著递增（Ｐ＜０．０５－０．００１）,而缺氧４０ｄ组基本与缺氧２１ｄ组持平,未再进一步升高。缺氧１ｄ组,各ＡＣｈ浓度（１０＾－１０,１０＾－９,１０＾－７,１０＾－６,１０＾－５ｍｏｌ／Ｌ）引起的内皮依赖性舒张反应明     

Selective inhibition of arachidonic acid metabolite release from human lung tissue by antiinflammatory steroids

The effects of antiinflammatory steroids on arachidonic acid metabolite release from human lung fragments were analyzed. Incubation of lung fragments for 24 hr with 10(-6) M dexamethasone inhibited the net release of the prostacyclin metabolite 6-keto-PGF1 alpha, PGE2, and PGF2 alpha from lung fragments stimulated with anti-IgE but failed to inhibit the anti-IgE-induced release of PGD2, TXB2, and iLTC4. The IC50 of dexamethasone for inhibition of both spontaneous and anti-IgE-induced 6-keto-PGF1 alpha release was approximately 2 X 10(-8) M, and a 6-hr preincubation with the drug was required for 50% inhibition of prostaglandin release. Other agents were tested for activity in stimulating arachidonic acid metabolite release from human lung fragments. FMLP (fmet-leu-phe) stimulated the release of all metabolites tested (6-keto-PGF1 alpha, PGD2, PGE2, PGF2 alpha, TXB2, iLTC4); platelet-activating factor (PAF), but not lysoPAF, stimulated the release of PGD2, TXB2, and iLTC4. In contrast to the case with anti-IgE, where dexamethasone failed to inhibit net PGD2 and TXB2 release, the steroid inhibited the release of these metabolites stimulated by both FMLP and PAF. The steroid inhibited iLTC4 release induced by the highest concentration of PAF (10(-6)M) but did not inhibit iLTC4 release stimulated by either 10(-7) M PAF, FMLP, or anti-IgE. Because neither FMLP nor PAF caused the release of PGD2 or TXB2 from purified human lung mast cells, and because they also failed to induce histamine release from lung fragments, it is suggested that these stimuli produce PGD2 and TXB2 release in lung fragments through an action on a cell distinct from the mast cell. This suggestion is supported by the selective inhibition of the release of these arachidonic acid metabolites by dexamethasone. We suggest that the inhibitory action of steroids on arachidonic acid metabolite in human lung fragments contributes to their therapeutic efficacy in pulmonary diseases.     

塞来昔布对慢性低O_2高CO_2大鼠肺动脉高压的影响及其机制研究

目的：探讨塞来昔布对慢性低O2高CO2大鼠肺动脉高压的作用。方法：将SD大鼠分为正常对照组,慢性低O2高CO2组,慢性低O2高CO2＋塞来昔布组。用电镜、放免等方法,观察各组大鼠肺动脉平均压、颈动脉平均压、肺细小动脉显微结构、血浆和肺匀浆血栓素B2（TXB2）及6-酮-前列腺素F1α（6-keto-PGF1α）含量的变化。结果：①慢性低O2高CO2组平均肺动脉压（mPAP）比正常组显著升高,塞来昔布组的mPAP比慢性低O2高CO2组显著升高,3组间平均颈动脉压（mCAP）比较差异无显著性。②慢性低O2高CO2组与正常对照组相比血浆和肺匀浆TXB2浓度、TXB2/6-keto-PGF1α比值显著增高,6-keto-PGF1α浓度显著下降;塞来昔布组与慢性低O2高CO2组相比血浆和肺匀浆TXB2浓度无明显变化、TXB2/6-keto-PGF1α显著升高,6-keto-PGF1α显著下降。③光镜下慢性低O2高CO2组与正常组相比,肺细小动脉管壁面积/管总面积（WA/TA）和肺细小动脉中膜厚度（PAMT）均显著增高。塞来昔布组与慢性低O2高CO2组相比WA/TA和PAMT显著增高。④电镜下慢性低O2高CO2组大鼠肺细小动脉内皮细胞吞饮小泡增多,血管壁增厚,中膜平滑肌细胞增生,纤维细胞增多,肺泡II型上皮细胞微绒毛脱落;塞来昔布组中膜平滑肌细胞增大、增多,胞浆肌丝丰富,平滑肌细胞间隙增宽,肺泡隔胶原纤维增生明显。结论：塞来昔布可能有加重慢性低O2高CO2性肺动脉高压和肺血管结构重建倾向,过度抑制COX-2,使TXA2/PGI2比值升高可能是其作用机制之一。     

Effects of alveolar hypoxia on the pulmonary circulation and lung mechanics after cromolyn sodium and U-60,257 in lambs.

Because alveolar hypoxia (HYP) triggers pulmonary mast cell degranulation with elaboration of vasoactive mediators such as leukotrienes, we investigated the effects of aerosolized cromolyn sodium (CS), a mast cell stabilizing agent, and U-60,257(U) (a leukotriene blocker) on the circulation, lung mechanics and thromboxane (TXB2) levels in 11 lambs during acute exposure to HYP. Studies were performed in awake, chronically instrumented animals, once after placebo (saline) and again after CS (100 mg; n = 5) or U (90 mg; n = 6). Pulmonary arterial pressure increased 42% during HYP after saline, and 32% and 19% after CS and U, respectively. Pulmonary vascular resistance did not change during HYP after CS or U. Systemic arterial pressure was unchanged after saline and CS but decreased after U; systemic vascular resistance dropped after both CS and U. No changes were seen in tidal volume, lung compliance or airway resistance during HYP after saline or either drug, but minute ventilation increased during HYP in all studies. TXB2 increased during HYP after saline in both studies and was not altered by CS. In contrast, after U, TXB2 decreased. Thus, U more effectively blunted the pulmonary vascular response to HYP than CS and resulted in mild systemic hypotension. The drop in TXB2 after U suggests leukotriene-induced thromboxane synthesis contributes to regulation of pulmonary, and possibly, systemic vasoactivity.     

Role of leukotriene C4 in pulmonary hypertension: platelet-activating factor vs. hypoxia

The aim of this study was to determine whether leukotriene C4 (LTC4) is a mediator of hypoxic pulmonary vasoconstriction. We hypothesized that similar increases in LTC4, detected in the lung parenchyma and pulmonary vascular compartment during cyclooxygenase blockade with indomethacin (INDO), would be observed during an equal increase in pulmonary arterial pressure caused by acute alveolar hypoxia (HYP, 100% N2) or platelet-activating factor (PAF, 10 micrograms into the pulmonary artery). Rat lungs were perfused at constant flow in vitro with an albumin-Krebs-Henseleit solution. Mean pulmonary arterial pressure (n = 6 per group) increased from a base line of 10.9 +/- 1.2 to 15.8 +/- 2.1 (HYP + INDO) and 15.5 +/- 1.9 (SE) Torr (PAF + INDO). LTC4 levels increased only in response to PAF + INDO; perfusate levels increased from 0.4 +/- 0.07 to 5.3 +/- 1.1 ng/40 ml, and lung parenchymal levels increased from 1.9 +/- 0.07 to 22.8 +/- 5.3 ng/lung. Diethylcarbamazine (lipoxygenase inhibitor) reduced PAF-induced lung parenchymal levels of LTC4 by 68% and pulmonary hypertension by 63%. We conclude that 1) LTC4 is not a mediator of hypoxic pulmonary vasoconstriction and 2) intravascular PAF is a potent stimulus for LTC4 production in the lung parenchyma.     

游泳运动对低氧性肺动脉高压大鼠肺组织apelin及其受体表达的影响

目的:探讨游泳运动对大鼠肺组织新的小分子活性肽apelin及其受体(APJ)表达的影响。方法:45只雄性大鼠随机分成三组:正常对照组、低氧组(七周)和游泳组(低氧+游泳锻炼七周组,低氧3周后,于每天入低氧舱前行无负重游泳运动60 min,每天1次)。七周后测定各组大鼠平均肺动脉压(mPAP)、右心室与左心室加室间隔的重量比[RV/(LV+S)]、肺细小动脉管壁面积/管总面积(WA/TA)、管腔面积/管总面积(CA/TA)及中膜厚度(PAMT)。免疫蛋白印迹与免疫组化法测定肺组织apelin/APJ的蛋白表达。结果:①低氧组mPAP和RV/(LV+S)比正常对照组分别高73.6%和31.2%(P均<0.01),而游泳组比低氧组分别低21.1%和8.9%(P均<0.05)。②低氧组WA/TA和PAMT较正常对照组分别高70.8%和102%,而游泳组较低氧组分别低24.8%和40.1%(P均<0.01)。低氧组CA/TA较正常对照组低15.1%,而游泳组较低氧组高10.3%(P均<0.01)。③低氧组肺组织apelin蛋白表达较正常对照组上调374%(P<0.01),而APJ蛋白表达下调87.1%(P均<0.01);游泳组肺组织apelin蛋白表达较低氧组下调48%,而APJ蛋白表达上调287%(P均<0.01)。④apelin蛋白主要在血管外膜及炎症细胞胞浆内表达,APJ蛋白主要在血管内膜、外膜及炎症细胞上表达。结论:游泳运动减缓肺动脉高压和肺血管重塑作用可能与调节肺组织apelin/APJ系统的表达有关。     

Relationship between PAF-acether and thromboxane A2 biosynthesis in endotoxin-induced intestinal damage in the rat

PAF-receptor antagonists are known to inhibit gastrointestinal damage induced by endotoxin. In the present study, the interaction between the biosynthesis of PAF and thromboxane (TX) A2, as putative mediators of the acute intestinal damage induced by endotoxin, has been investigated in the anaesthetised rat. Bolus intravenous administration of lipopolysaccharide from E. coli (5-50 mg/kg) induced dose-related jejunal damage, assessed using both macroscopic and histological techniques. This damage was accompanied by significant increases in the jejunal formation of PAF determined by bioassay, and of TXB2, determined by radioimmunoassay. Pretreatment with the structurally-unrelated thromboxane synthase inhibitors, 1-benzyl imidazole (10-50 mg/kg) or OKY 1581 (25 mg/kg) substantially reduced both jejunal damage and TXB2 formation, but did not inhibit PAF formation. Likewise, pretreatment with indomethacin (5 mg/kg) or BW 755C (50 mg/kg) reduced jejunal damage and TXB2 formation but did not affect PAF formation. Pretreatment (2h) with dexamethasone (4 mg/kg) reduced jejunal damage and the formation of both TXB2 and PAF. Intravenous infusion of PAF (100 ng/kg/min for 10 min) induced jejunal damage and significantly increased the formation of TXB2, whereas non-specific jejunal damage induced by oral administration of ethanol did not augment PAF formation. The present findings that inhibition of jejunal thromboxane formation is associated with a substantial reduction in jejunal damage, with no corresponding inhibition in PAF formation, therefore suggests a complex interaction or sequential release of these tissue destructive mediators underlying the intestinal damage induced by endotoxin.     

Pulmonary responses to phospholipase A2 in the perfused guinea pig lung

We examined the effect of phospholipase A2 (PLA2; Naja naja) challenge on pulmonary hemodynamics, airway constriction, and fluid filtration in isolated Ringer-perfused guinea pig lungs. Intratracheal PLA2 (10-100 U) produced dose-dependent increases in pulmonary arterial pressure, intratracheal pressure, and lung weight, although intravenous PLA2 administration had no effect on monitored variables. Morphological features indicative of airway constriction and pulmonary edema were observed by light microscopy. PLA2-induced increases in intratracheal pressure and/or lung weight were attenuated to varying degrees by pretreatment with indomethacin (1 microM, a cyclooxygenase inhibitor), ICI-198,615 (1 microM, a leukotriene D4 receptor antagonist), and WEB 2086 (1 microM, a platelet-activating factor antagonist). PLA2-induced increases in pulmonary arterial pressure and intratracheal pressure were also reduced in lungs removed from animals pretreated with dexamethasone (50 mg/kg ip for 2 days; a steroidal antiinflammatory agent). Pyrilamine (1 microM, a histamine1-receptor antagonist) and Takeda AA861 (1 microM, a delta 5-lipoxygenase inhibitor) did not produce significant inhibitory effects on PLA2-induced pathophysiological changes. Intratracheal instillation of high-dose platelet-activating factor (50 micrograms) or lysophosphatidylcholine (100 micrograms) produced gradual increases in intratracheal pressure and lung weight, but these changes were not as large as those induced by PLA2. Thus these studies suggest that resident cell populations associated with airways may play an important role in PLA2-induced pathophysiological changes in the perfused guinea pig lung. These PLA2-induced effects are most likely partially mediated by generation of eicosanoids and platelet-activating factor.     

Are lipid mediators implicated in the production of pro- and anti-inflammatory cytokines during cardiopulmonary bypass graft with extracorporeal circulation?

In this study the authors assessed the sequential release of lipid mediators (TXB2, PGE2, 6-keto-PGF1alpha, LTB4, LTC4, PAF), pro-inflammatory cytokines (IL-6, IL-8, TNF-alpha) and anti-inflammatory cytokines (IL-4, IL-10) in 17 patients undergoing coronary artery bypass graft (CABG) with extracorporeal circulation (ECC). Time course of appearance of inflammatory mediators revealed the early and transient increase in lipid mediator plasma concentrations (6-keto-PGF1alpha, LTB4, LTC4, PAF) whereas cytokines (IL-6, IL-8, IL-10) were involved only in late pre- and post-operative periods. No variation of TXB2, PGE2, IL-4 and TNF-alpha levels were found. No correlation was documented between the levels of lipid mediators and pro- or anti-inflammatory cytokines suggesting that lipidic compounds are not implicated in the genesis of cytokines which appear much later involved. Despite the common use of high doses of aprotinin (a non-specific enzyme inhibitor) in hope to abrogate the inflammatory response to cardiopulmonary bypass procedure, this study reports the persistent release of several inflammatory compounds that might be involved in the post-CABG multiple organ failure syndromes.     

甘西鼠尾草对大鼠高原肺动脉高压的干预作用及机制*

目的:探讨甘西鼠尾草(SPM)对大鼠高原肺动脉高压(HAPH)的干预作用及可能的机制。方法:将雄性SD大鼠随机分成对照组、缺氧组、SPM(0.5 g/kg、1 g/kg、2 g/kg)剂量组,每组14只,对照组饲养于西宁(海拔约2260 m),其余组均饲养于玛多县人民医院(海拔约4260 m)。SPM剂量组灌胃不同浓度的SPM(1 ml/100 g),浓度分别为0.5 g/kg、1 g/kg、2 g/kg,对照组和缺氧组灌胃等体积蒸馏水,每日一次,连续4周后,测定大鼠平均肺动脉压(mPAP)并取相同部位肺组织置液氮保存备用。采用RT-PCR法测定每组大鼠肺组织中的细胞增殖核抗原(PCNA)、细胞周期素依赖激酶(CDK4)、细胞周期蛋白D(CyclinD1)、RhoA(Ras同源基因家族成员A)、ROCK1、ROCK2的mRNA表达水平。结果:与对照组比较,缺氧组大鼠mPAP、肺组织中PCNA、CDK4、CyclinD1、RhoA、ROCK1、ROCK2的mRNA表达水平均明显升高(P＜0.01)。与缺氧组比较,SPM剂量组大鼠的mPAP、肺组织中PCNA、CDK4、CyclinD1、RhoA、ROCK1、ROCK2的mRNA表达水平均明显降低(P＜0.05或P＜0.01)。结论:SPM对大鼠HAPH具有一定的预防作用,其机制可能与抑制肺动脉平滑肌细胞过度增殖和RhoA/Rho激酶(ROCK)信号通路过度激活有关。     

SENP1在大鼠低氧性肺动脉高压形成中肺血管壁中表达及可能作用

目的:探讨大鼠低氧性肺动脉高压(HPH)形成过程中SENP1在肺小动脉的动态表达变化及作用。方法:40只成年雄性Wistar大鼠随机分为5组(n=8):对照组和缺氧3 d、7 d、14 d2、1 d组,常压间断低氧复制HPH大鼠模型。测各组大鼠平均肺动脉压(mPAP)、右心室肥大指数(RVHI)、血管形态学指标;原位杂交、逆转录-聚合酶链反应(RT-PCR)检测肺内SUMO特异性蛋白酶-1(SUMO-specific proteases-1,SENP1)mRNA表达,免疫组化、Westernblot检测其蛋白质水平。结果:①缺氧7 d后,肺小动脉出现血管重塑,且mPAP明显上升;低氧14 d后,肺小动脉重塑更明显,mPAP达高峰。RVHI在低氧14 d后明显增加。②原位杂交显示,SENP1 mRNA在对照组肺小动脉壁呈阳性表达,低氧后其相对量无明显变化。RT-PCR显示肺组织SENP1 mRNA表达与原位杂交所观察到的肺小动脉壁SENP1 mRNA变化趋势一致;SENP1蛋白在对照组呈阳性表达,低氧7 d后其表达量开始呈进行性下降。Western blot显示肺组织内SENP1蛋白表达与免疫组化观察到的肺小动脉壁SENP1蛋白变化趋势一致。③SENP1蛋白与mPAP、重塑指数、RVHI均呈负相关。结论:慢性低氧诱导肺小动脉壁SENP1蛋白降解,进而可能在HPH发病过程中发挥一定的作用。